ADVANCED MEDICAL TECHNOLOGIES INC/CANADA
10QSB, 2000-09-18
NON-OPERATING ESTABLISHMENTS
Previous: HONDA AUTO LEASE TRUST 1999A, 8-K, EX-20, 2000-09-18
Next: AMERI-CAN RAILWAY SYSTEMS INC, 10QSB, 2000-09-18






                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                                   FORM 10-QSB

(X )     QUARTERLY  REPORT  PURSUANT  TO SECTION 13 OR 15(D) OF THE  SECURITES
         EXCHANGE ACT OF 1934

For the quarterly period ended         July 31, 2000
                               --------------------------

(  )     TRANSITION  REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES
         EXCHANGE ACT OF 1934

For the transition period from                   to
                               ------------------     --------------------

Commission File number              0-28571
                       --------------------------------------


                           ADVANCED MEDICAL TECHNOLOGIES INC.
              -----------------------------------------------------------
               (Exact name of registrant as specified in charter)


            Nevada                                            98-0206212
------------------------------------                ----------------------------
(State or other jurisdiction of                           (I.R.S. Employer
incorporation or organization)                            Identification No.)

Suite 200 - 5925 Airport Road
Toronto, Ontario, Canada                                      L4V 1W1
------------------------------------                  --------------------------
(Address of principal executive offices)                      (Zip Code)

                                  905-405-6280
              ----------------------------------------------------
               Registrant's telephone number, including area code

      ---------------------------------------------------------------------
      (Former name, address, and fiscal year, if changed since last report)

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such  reports),  Yes [X] No [ ] and ( ) has been
subject to filing requirements for the past 90 days. Yes [X] No [ ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the last practicable date.

                  Class                          Outstanding as of July 31, 2000
    -----------------------------------          -------------------------------
       Common Stock, $0.001 per share                       14,197,300


<PAGE>


ANDERSEN ANDERSEN & STRONG, L.C.                   941 East 3300 South, Suite202
--------------------------------                      Salt Lake City, Utah 84106
Certified Public Accountants and Business Consultants
                                                          Telephone 801-486-0096
                                                                Fax 801-486-0098

REPORT ON REVIEW BY INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS


The Board of Directors
Advanced Medical Technologies Inc.

We have reviewed the condensed  balance sheet of Advanced  Medical  Technologies
Inc.  (development  stage  company) as of July 31, 2000 and January 31, 2000 and
the related  condensed  statements of operations and the condensed  statement of
cash  flows for the three and six months  ended  July 31,  2000 and 1999 and the
period  February 3, 1999 (date of inception) to July 31, 2000.  These  financial
statements are the responsibility of the company's management.

We conducted our review in accordance with standards established by the American
Institute  of  Certified  Public  Accountants.  A review  of  interim  financial
information consists principally of applying analytical  procedures to financial
data and making  inquiries of persons  responsible  for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with  generally  accepted  auditing  standards,  the  objective  of which is the
expression of an opinion  regarding the financial  statements  taken as a whole.
Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material  modifications that should
be made to the  accompanying  financial  statements for them to be in conformity
with generally accepted accounting principles.

                                            /s/   "Andersen Andersen and Strong"

Salt Lake City, Utah
September 15, 2000

<PAGE>

                                      INDEX
<TABLE>
<CAPTION>

                                                                                                        Page
PART 1.                                                                                               Number
                                                                                                      ------

<S>                                                                                                     <C>
         ITEM 1.  Financial Statements (unaudited).........................................             3

                  Balance Sheet............................................................             4
                     July 31, 2000 and January 31, 2000

                  Statement of Operations
                     For   the three  months  ended  July 31,  2000 and
                        1999, the six months ended July 31, 2000 and
                        1999 and the period February 3, 1999 to July 31, 2000 ..............            5

                  Statement of Cash Flows
                     For the six months ended July 31, 2000 and 1999........................            6
                        and the period February 3, 1999 to July 31, 2000

                  Notes to the Financial Statements.........................................            7

         ITEM 2.  Management Discussion and Analysis........................................            9


PART 11           Other information........................................................

                  Signatures...............................................................            10

</TABLE>

<PAGE>


                         PART 1 - FINANCIAL INFORMATION
--------------------------------------------------------------------------------
                          ITEM 1. FINANCIAL STATEMENTS
--------------------------------------------------------------------------------

The  accompanying   balance  sheet  of  Advanced  Medical   Technologies,   Inc.
(development  stage  company)  at July 31,  2000 and  January  31,  2000 and the
statement of operations  for the three months ended July 31, 2000 and 1999,  the
six months ended July 31, 2000 and 1999 and the period February 3, 1999 (date of
inception) to July 31 ,2000, the statement of cash flows for the six month ended
July 31, 2000 and 1999,  and the period from  February 3, 1999 to July 31, 2000,
have been  prepared  by the  Company's  management  and they do not  include all
information  and notes to the  financial  statements  necessary  for a  complete
presentation of the financial position, results of operations, and cash flows in
conformity  with generally  accepted  accounting  principles.  In the opinion of
management,  all adjustments considered necessary for a fair presentation of the
results of  operations  and  financial  position have been included and all such
adjustments are of a normal recurring nature.

Operating  results  for the quarter  ended July 31,  2000,  are not  necessarily
indicative  of the results that can be expected for the year ending  January 31,
2001.






                                       3

<PAGE>

                       ADVANCED MEDICAL TECHNOLOGIES INC.
                           (Development Stage Company)

                                 BALANCE SHEETS

                       July 31, 2000 and January 31, 2000
<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------
                                                                                  JULY 31,             Jan. 31
                                                                                     2000                2000
                                                                                     ----                ----
<S>                                                                               <C>                 <C>
   ASSETS

   CURRENT ASSETS

        Cash                                                                      $     1,143         $     661
                                                                                    ---------           -------
             Total Current Assets                                                 $     1,143         $     661
                                                                                    =========           =======

   LIABILITIES AND STOCKHOLDERS' EQUITY

   CURRENT LIABILITIES

         Accounts payable - related parties                                       $   19,422          $   1,000
         Accounts payable                                                             12,146              4,401
                                                                                     -------             ------

            Total Current Liabilities                                                 31,568              5,401
                                                                                    --------              -----

   STOCKHOLDERS' EQUITY

        Common stock
              200,000,000 shares authorized, at $0.001 par
              value, 14,197,300 shares issued and outstanding                          14,197              14,197

        Capital in excess of par value                                                 29,488              29,488

        Deficit accumulated during the development stage                              (74,110)           (48,425)
                                                                                     --------           ---------

              Total Stockholders' Equity (Deficiency)                                 (30,425)            (4,740)
                                                                                     --------             -------

                                                                                  $      1,143       $       661
                                                                                     =========            ======
</TABLE>

The  accompanying  notes are an  integral  part of these financial statements.





                                       4

<PAGE>


                       ADVANCED MEDICAL TECHNOLOGIES INC.
                           (Development Stage Company)

                             STATEMENT OF OPERATIONS

  For the three months ended July 31, 2000 and 1999, for the six months ended
                    July 31, 2000 and 1999 and for the period
                        February 3, 1999 to July 31, 2000

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------------
                                                     THREE           MONTHS            SIX         MONTHS     FEB. 3, 1999
                                                    JULY 31         JULY 31         JULY 31       JULY 31,     TO JULY 31
                                                     2000             1999           2000           1999            2000
                                                     ----             ----           ----           ----            ----
<S>                                          <C>              <C>            <C>             <C>            <C>
REVENUES                                      $        --      $        --      $      --     $        --    $       --
                                               ----------        ---------       --------       ---------      --------

EXPENSES                                           16,814           10,075         25,685          15,730        74,110
                                               ----------        ---------       --------       ---------      --------

NET LOSS                                      $   (16,814)     $   (10,075)     $ (25,685)     $  (15,730)    $ (74,110)
                                               ==========        =========       ========        ========      ========

NET LOSS PER COMMON SHARE

     Basic                                    $        --      $        --      $      --      $       --
                                               ----------        ---------       --------        --------

AVERAGE OUTSTANDING SHARES

     Basic                                     14,197,300       14,197,300     14,197,300
                                               ==========       ==========     ==========

</TABLE>


The  accompanying  notes are an  integral  part of these financial statements.



                                       5

<PAGE>

                       ADVANCED MEDICAL TECHNOLOGIES INC.
                          (A Development Stage Company)

                             STATEMENT OF CASH FLOWS

                            For the six months ended
                    July 31, 2000 and 1999 and for the period
           from February 3, 1999 (Date of Inception) to July 31, 2000

                      (Unaudited - Prepared by Management)

<TABLE>
<CAPTION>

                                                            FOR THE SIX         FOR THE SIX             FROM INCEPTION
                                                            MONTHS ENDED        MONTHS ENDED                   TO
                                                           JULY 31, 2000       JULY 31, 1999             JULY 31, 2000
                                                           -------------       -------------             -------------
<S>                                                           <C>               <C>                    <C>

     CASH FLOWS FROM
          OPERATING ACTIVITIES

          Net loss                                            $   (25,685)      $    (15,730)           $    (74,110)

          Adjustments to reconcile net loss to net
             cash provided by operating activities:

             Increase in accounts payable                           7,745             (2,505)                 12,146
             Capital contribution - expenses                           --              2,700                  10,800
                                                                 --------           ---------                 -------

          Net Cash (Deficiency) from Operations                   (17,940)           (15,535)                 (51,164)
                                                                 --------           --------                  -------

     CASH FLOWS FROM INVESTING
      ACTIVITIES:                                                      --                 --                       --
                                                                 --------           --------                  -------
     CASH FLOWS FROM FINANCING
      ACTIVITIES:

        Proceeds from loans - related parties                      18,422                 --                   19,422
        Proceeds from issuance of common
          Stock                                                        --             23,459                   32,885
                                                                 --------           --------                  -------
      Net Increase in Cash                                            482              7,924                    1,143

      Cash at Beginning of Period                                     661                 --                       --
                                                                 --------           --------                  -------

      CASH AT END OF PERIOD                                   $     1,143        $     7,624            $       1,143
                                                                 ========           ========                  =======
</TABLE>

The  accompanying  notes  are an  integral  part of  these  unaudited  financial
                                   statements.


                                       6

<PAGE>

                       ADVANCED MEDICAL TECHNOLOGIES INC.
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS

                                  July 31, 2000

                      (Unaudited - Prepared by Management)

1.       ORGANIZATION

         The Company was  incorporated  under the laws of the State of Nevada on
         February 3, 1999 with the authorized common stock of 200,000,000 shares
         at $0.001 par value.

         The Company was organized for the purpose of  establishing a multimedia
         internet based  communications  network between the healthcare industry
         manufacturers  and  the key  case  managers  in the  medical  field  to
         advertise and promote the manufacturers' products.

         The Company is in the development stage.

         Since its,  inception the Company has completed  Regulation D offerings
         of 14,197,300 shares of its capital stock for cash.

2.       SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

         Accounting Methods

         The Company  recognizes income and expenses based on the accrual method
         of accounting.

         Dividend Policy

         The  Company  has  not  yet  adopted  a  policy  regarding  payment  of
         dividends.

         Income Taxes

         On July 31, 2000 the Company had a net operating  loss carry forward of
         $74,110.  The tax  benefit  from the loss carry  forward has been fully
         offset by a valuation reserve because the use of the future tax benefit
         is doubtful since the Company is in the  development  stage and has not
         started operations. The net operating loss will expire in 2022.

         Earnings (Loss) per Share

         Earnings  (Loss) per share  amounts are computed  based on the weighted
average number of shares actually outstanding.


                                       7

<PAGE>

                       ADVANCED MEDICAL TECHNOLOGIES INC.
                          (A Development Stage Company)

                          NOTES TO FINANCIAL STATEMENTS

                                  July 31, 2000

                      (Unaudited - Prepared by Management)

2.       SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED

         Comprehensive Income

         The Company  adopted  Statement of Financial  Accounting  Standards No.
         130.  The  adoption  of  this  standard  had no  impact  on  the  total
         stockholder's equity.

         Recent Accounting Pronouncements

         The  Company  does  not  expect  that  the  adoption  of  other  recent
         accounting  pronouncements will have a material impact on its financial
         statements.

         Financial Instruments

         The  carrying  amounts of  financial  instruments,  including  cash and
         accounts  payable are  considered by  management to be their  estimated
         fair values.

         Estimates and Assumptions

         Management  uses  estimates  and  assumptions  in  preparing  financial
         statements in accordance with generally accepted accounting principles.
         Those  estimates  and  assumptions  affect the reported  amounts of the
         assets  and  liabilities,  the  disclosure  of  contingent  assets  and
         liabilities,  and the reported  revenues and expenses.  Actual  results
         could vary from the  estimates  that were  assumed in  preparing  these
         financial statements.

3.       RELATED PARTY TRANSACTIONS

         Related parties acquired 43% of the common stock issued.

5.       GOING CONCERN

         Management  is  planning  to  establish  a  multimedia  internet  based
         communications  network for the medical field. To be successful in this
         effort the Company will need additional working capital.

         Continuation  of the  Company  as a going  concern  is  dependent  upon
         obtaining  additional working capital and the management of the Company
         has  developed  a  strategy,  which it believes  will  accomplish  this
         objective through  additional equity funding,  and long term financing,
         which will enable the Company to operate for the coming year.

         There can be no assurance  that  management  will be successful in this
         effort.


                                       8

<PAGE>
--------------------------------------------------------------------------------
                           ITEM 2. PLAN OF OPERATIONS
--------------------------------------------------------------------------------

The Company's  management is in the process of reviewing the various  options it
has available to develop the Company. To date there has not been a great deal of
interest in the Company's  project and no customers  have  indicated a desire to
use  the  facilities  of the  Company's  web  sit on  the  Internet.  Therefore,
management is considering  other avenues whereby it could develop a revenue flow
to meet its monthly expenses.

Liquidity and Capital Resources

The Company will need additional working capital to finance its activities.  The
additional working capital may be obtained through additional equity funding and
long term  financing or maybe by way of loans or advances from its directors and
officers.

Results of Operations

The Company has had no operations during this reporting period.



                                       9

<PAGE>

                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                              ADVANCED MEDICAL TECHNOLOGIES INC.
                                                        (Registrant)

September 15, 2000                                   /s/  "Michael G. Fisher"
                                              ----------------------------------
                                                           Michael G. Fisher
                                                              Director







                                       10



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission